文献速递湿疹皮炎与荨麻疹

儿童特应性皮炎的microRNA分析揭示miR-451a的作用

MicroRNA analysis of childhood atopic dermatitis reveals a role for miR-451a.
PubMed 文献 · Br J Dermatol · 2020-07-27

该研究通过小RNA测序和HTG EdgeSeq系统分析婴儿特应性皮炎(AD)患者外周血单核细胞(PBMC)和血浆中的miRNA表达谱,并与年龄匹配的健康对照比较。发现PBMC中10个miRNA差异表达,血浆中8个miRNA失调,其中miR-451a在两种血成分中均差异表达,并被鉴定为早期诊断AD的预测性生物标志物。实验验证的miR-451a靶点IL6R和PSMB8在AD患者中升高,与miR-451a水平负相关。

要点

  • 婴儿AD患者外周血存在独特的miRNA表达特征,提示疾病的全身性效应。
  • miR-451a在AD患者PBMC和血浆中均差异表达,可能作为早期诊断AD的新型生物标志物。
  • miR-451a的靶点IL6R和PSMB8在AD患者中升高,且与miR-451a水平负相关。

核心结论

  • 婴儿AD患者外周血存在独特的miRNA特征,miR-451a可能作为早期诊断AD的新型生物标志物。

研究设计与样本

  • 研究采用小RNA测序和HTG EdgeSeq系统分析婴儿AD患者与年龄匹配健康对照的PBMC和血浆miRNA表达谱。
  • 使用逆转录定量实时PCR(RT-qPCR)验证并测量miRNA靶点。
  • 采用逻辑回归模型和受试者工作特征曲线下面积评估所选miRNA对AD的诊断潜力。

主要发现

  • 在AD婴儿的PBMC中鉴定出10个差异表达的miRNA,血浆中鉴定出8个失调的miRNA。
  • PBMC中上调的miRNA包括与炎症相关的miR-223-3p、miR-126-5p和miR-143-3p。
  • 仅miR-451a在AD患儿的PBMC和血浆中均差异表达。
  • 在更大样本中验证了miR-451a、miR-143-3p和miR-223-3p的失调,并确定miR-451a为早期诊断的预测性生物标志物。
  • 实验验证的miR-451a靶点IL6R和PSMB8在AD患者中升高,与miR-451a水平负相关,且在PBMC中抑制miR-451a后上调。

临床怎么用

  • miR-451a可能作为婴儿AD早期诊断的潜在生物标志物,但需进一步临床验证。
  • 外周血miRNA特征反映了AD的全身性效应,提示miRNA可能参与疾病发病机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MicroRNAs (miRNAs), important regulators of gene expression, have been implicated in a variety of disorders. The expression pattern of miRNAs in paediatric atopic dermatitis (AD) has not been well studied. OBJECTIVES: We sought to investigate miRNA expression profiles in different blood compartments of infants with AD. METHODS: Small RNA and analysis with the HTG EdgeSeq system were performed to identify differentially expressed miRNAs in peripheral blood mononuclear cells (PBMCs) and plasma of infants with AD vs. age-matched healthy controls, with reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) used for validation and measurement of miRNA targets. Logistic regression models with area under the receiving operating characteristic estimation was used to evaluate the diagnostic potential of chosen miRNAs for AD. RESULTS: RNA sequencing was performed to access miRNA expression profiles in paediatric AD. We identified 10 differentially expressed miRNAs in PBMCs and eight dysregulated miRNAs in plasma of infants with AD compared with controls. Upregulated miRNAs in PBMCs included miRNAs known to be involved in inflammation: miR-223-3p, miR-126-5p and miR-143-3p. Differential expression of only one miRNA, miR-451a, was observed in both PBMCs and plasma of children with AD. Dysregulation of three miRNAs (miR-451a, miR-143-3p and miR-223-3p) was validated in larger numbers of samples and miR-451a was identified as a predictive biomarker for the early diagnosis of the disease. Experimentally verified targets of miR-451a, interleukin 6 receptor (IL6R) and proteasome subunit beta type-8 (PSMB8), were increased in patients with AD, negatively correlated with miR-451a levels and upregulated following inhibition of miR-451a in PBMCs. CONCLUSIONS: In infants with AD, a distinct peripheral blood miRNA signature is seen, highlighting the systemic effects of the disease. miR-451a is uniquely expressed in different blood compartments of patients with AD and may serve as a promising novel biomarker for the early diagnosis of AD.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Nousbeck J, McAleer MA, Hurault G, et al. MicroRNA analysis of childhood atopic dermatitis reveals a role for miR-451a. Br J Dermatol. 2020. PMID: 32478410. doi:10.1111/bjd.19254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。